艾德生物(300685.SZ):實時熒光定量PCR分析儀獲得醫療器械註冊證
格隆匯6月12日丨艾德生物(300685.SZ)公佈,公司於近日獲得由國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,產品名稱為實時熒光定量PCR分析儀。
該產品基於實時熒光PCR檢測原理,與配套的檢測試劑共同使用,在臨牀上用於對來源於人體樣本中的靶核酸(DNA/RNA)進行定性、定量檢測,包括病原體和人類基因項目。實時熒光定量PCR分析儀(GEMINI)雙倍通量,操作簡便快捷,具備自動報吿功能,能更好的滿足腫瘤精準診斷多基因聯檢需求。
該產品醫療器械註冊證的取得,進一步完善了公司以伴隨診斷試劑為核心,打造從上游的樣本處理/核酸提取,到檢測端的試劑儀器,再到下游的自動報吿/數據管理系統的腫瘤精準檢測整體解決方案,有利於持續擴大公司綜合競爭優勢,對公司未來的發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.